HIGHLIGHTS
- who: Zenglei Zhang from the Queen Mary University of London, United Kingdom have published the research work: Role of inflammation, immunity, and oxidative stress in hypertension: New insights and potential therapeutic targets, in the Journal: (JOURNAL)
- what: The main reason that canakinumab does not lower the blood pressure may be related to the enrolled populations of whom 80% are patients with hypertension and were taking antihypertensive drugs, which may mask the real antihypertensive effect of canakinumab.
- future: In several large-scale clinical trials the effect of supplementation of vitamin C on blood pressure . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.